Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Massard

Showing results (41-50 of 87) with videos related to

Pageof 9
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 2009
Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancerC Serrate, Y Loriot, T De La Motte Rouge, et al.
Prostate Cancer and Prostatic Diseases|October 15, 2014
Who dies from prostate cancer?A Patrikidou, Y Loriot, J-C Eymard, et al.
Bulletin Du Cancer|December 22, 2009
[New drugs in metastatic castration-resistant prostate cancer]L Albiges, Y Loriot, M Gross-Goupil, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 22, 2008
The postchemotherapy PSA surge syndromeR Thuret, C Massard, M Gross-Goupil, et al.
BMC Cancer|March 1, 2016
Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancerC R Lindsay, S Le Moulec, F Billiot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 15, 2009
Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapyR de Crevoisier, K Slimane, T Messai, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 30, 2012
Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumorsC Massard, A Kramar, J Beyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 25, 2009
Why do residents choose the medical oncology specialty? Implications for future recruitment--results of the 2007 French Association of Residents in Oncology (AERIO) SurveyY Loriot, L Albiges-Sauvin, D Dionysopoulos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 31, 2010
ERCC1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapyB Besse, C Massard, V Haddad, et al.
British Journal of Cancer|August 19, 2010
A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumoursE Boven, C Massard, J P Armand, et al.
Pageof 9

Showing results (41-50 of 87) with videos related to

Sort By:
Pageof 9
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 2009
Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancerC Serrate, Y Loriot, T De La Motte Rouge, et al.
Prostate Cancer and Prostatic Diseases|October 15, 2014
Who dies from prostate cancer?A Patrikidou, Y Loriot, J-C Eymard, et al.
Bulletin Du Cancer|December 22, 2009
[New drugs in metastatic castration-resistant prostate cancer]L Albiges, Y Loriot, M Gross-Goupil, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 22, 2008
The postchemotherapy PSA surge syndromeR Thuret, C Massard, M Gross-Goupil, et al.
BMC Cancer|March 1, 2016
Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancerC R Lindsay, S Le Moulec, F Billiot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 15, 2009
Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapyR de Crevoisier, K Slimane, T Messai, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 30, 2012
Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumorsC Massard, A Kramar, J Beyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 25, 2009
Why do residents choose the medical oncology specialty? Implications for future recruitment--results of the 2007 French Association of Residents in Oncology (AERIO) SurveyY Loriot, L Albiges-Sauvin, D Dionysopoulos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 31, 2010
ERCC1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapyB Besse, C Massard, V Haddad, et al.
British Journal of Cancer|August 19, 2010
A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumoursE Boven, C Massard, J P Armand, et al.
Pageof 9